10x Genomics (TXG) Receivables (2018 - 2026)

10x Genomics has disclosed Receivables across 9 years of filings, most recently posting $56.1 million for Q1 2026.

• Receivables for Q1 2026 came in at $56.1 million, up 6.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.1 million (up 6.83% YoY), and the FY2025 annual result was $82.5 million, down 6.75% from the prior year.
• Receivables came in at $56.1 million for Q1 2026 at 10x Genomics, down from $82.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $119.1 million in Q2 2025 to a low of $52.5 million in Q1 2025.
• The 5-year median for Receivables is $87.7 million (2023), against an average of $87.4 million.
• Across the five-year window, Receivables surged 33.3% in 2022 and sank 42.45% in 2025, its largest moves.
• 10x Genomics' Receivables stood at $104.2 million in 2022, then increased by 10.19% to $114.8 million in 2023, then slipped by 22.96% to $88.5 million in 2024, then declined by 6.75% to $82.5 million in 2025, then plunged by 31.95% to $56.1 million in 2026.
• The last three Receivables figures came in at $56.1 million (Q1 2026), $82.5 million (Q4 2025), and $96.6 million (Q3 2025), per Business Quant data.